Interestingly, KDM5D deletion from cancer cells may decrease cancer invasiveness and enhance CD8+ T cell-killing activity; hence, it can be a promising therapeutic approach for CRC male patients expressing mutant KRAS33. This evidence concerns the gene CD8A and cancer.